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Recently, and for the first time in the past 
30 years, the incidence of spontaneous preterm 
birth (sPTB) in the USA has decreased from 
12.8% in 2006, to 11.7% in 2011 [1]. The rea-
sons for this decrease are not well known, but 
in the last two decades, great efforts have been 
made in order to find an effective screening 
test to identify women that are at higher risk of 
sPTB. Although a major risk factor for sPTB is 
a previous sPTB, it is also recognized that the 
majority of women who have experienced sPTB 
did not have a previous sPTB in their history.
Predicting sPTB through study of the cervix is 
the conclusion of dozens of ultrasound  studies, 
which show that the cervix starts to shorten 
weeks before delivery. The process begins at the 
internal os, and early detection of these changes 
can be crucial for intervention. By the time 
shortening is recognizable, a marked micro-
structural change has already occurred [2]. In 
fact, cervical softening is another critical process 
that precedes labor and sPTB, as well as cervi-
cal shortening. Recently, current data suggest 
that cervical microstructural changes also occur 
during specific stages of cervix remodeling: tis-
sue hydration, collagen structure, and tissue 
elasticity all change progressively with cervi-
cal remodeling. Hydration increases, collagen 
disorganizes and elasticity (softness) increases 
before labor [3]. Traditionally, both shortening 
and softening of the cervix have been evaluated 
by digital examination, which is subjective and 
suffers from a wide variability among examiners 
[4,5]. Moreover, the clinical usefulness of non-
objective tests in assessing cervical softening is 
still limited by practical and economic issues. 
Ultrasound cervical sonography, in contrast, is 
supported by ample evidence as a method for 
assessing cervical length (CL) as a screening test 
in the prediction of sPTB [6,7].
The objectives of this review are to assess tech-
nical and clinical aspects of transvaginal cervical 
sonography; factors that affect the value of CL in 
the prediction of sPTB: gestational age, patient 
obstetrical and medical history, symptoms and 
the number of fetuses, and the value of CL in 
addressing therapeutic strategies to prevent PTB.
The authors searched PubMed, Ovid, 
EMBASE and Cochrane for all articles with key 
words ‘cervical length’, ‘prediction of  preterm 
birth’, ‘prevention of preterm birth’, ‘transvagi-
nal ultrasound’. Preference was given to articles 
that were randomized trials or meta-analyses of 
such randomized studies.
Technical & clinical aspects of 
transvaginal cervical sonography
Transvaginal ultrasonography (TVU) CL 
 assessment is the gold standard and preferred 
screening test for a short cervix. TVU is more 
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sensitive than transabdominal ultrasound. Transabdominal meas-
urements overestimate CL by 8 mm among women with a short 
cervix, and have resulted in underdiagnosis of 57% of cases [8,9]. 
Transperineal or translabial ultrasound, a noninvasive technique, 
has also been proposed. However, it is limited because gas in the 
rectum may obstruct the view of the external os [10].
The appropriate technique to measure CL accurately using TVU 
requires the insertion of a clean probe covered by a condom in the 
anterior fornix of the vagina, after the woman has emptied her 
bladder [11]. When a sagittal long-axis view of the entire endocer-
vical canal has been obtained, the probe can then be withdrawn 
slowly until the image loses its focus. At this point, slight pressure 
has to be given in order to obtain the image again, which should 
then be enlarged until the cervix occupies at least two-thirds of 
the screen and both the external and internal os are seen. Excessive 
pressure on the cervix can elongate it. CL has to be measured from 
the internal to the external os along the endocervical canal. It 
appears as a line of echodensity between the two ora. After obtain-
ing three measurements, the shortest measurements in millimeters 
should be recorded. Then, a transfundal pressure for 15 s has to 
be applied before recording CL again at least three-times. TVU 
measurements are affected by the degree of pressure applied with 
the ultrasound transducer on the cervix, which can slightly change 
the orientation and measurements. TVU CL is not affected by 
maternal obesity, position of the cervix or shadowing from the 
fetal presenting part [12,13]. Maternal age, uterine contractions and 
cervical dynamic changes can also affect the measurement [14,15]. It 
has been reported that women younger than 20 years of age have 
longer cervices than older women [14], and that uterine contractility 
and bowel  peristalsis can modify CL by up to 5 mm [15].
The recommended scan time is at least 5 min, and the shortest 
and best CL has to be reported for clinical management [11]. The 
interobserver variability is 5–10% [16].
The rate of failed images of CL ranges between 10 and 20%, 
and skill is required for accurate TVU CL measurement [17,18]. 
It has also been suggested that providers need to be specifically 
trained in order to perform TVU CL [101,102]. In spite of statisti-
cally significant differences in CL between nulliparous and mul-
tiparous women, these differences are clinically unimportant [7].
The anatomic relationship of the sonographic internal os to the 
low uterine segment defines the shape of the sonographic junction, 
and it is qualitatively described as a T, Y, V or U [19].
Moving from a T to U shape increases the severity of the find-
ing. The TVU report may include funneling of the sonographic 
internal os, so that the following parameters may be reported: 
functional CL, which is the closed part of the cervix; funnel 
length, which is the open part of the cervix and funnel width 
(Figure 1) [20]. Studies have established that progressive cervical 
effacements precede uterine contraction by several weeks in both 
normal and sPTB [21,22]. Overall, functional CL is the preferred 
method in establishing the risk of sPTB, considering that, if 
 funneling is present, the CL is almost always short (Figure 2).
TVU can also help in recognizing other ultrasound risk indica-
tions for preterm delivery, including intra-amniotic sludge and cho-
riodecidual separation [23,24]. Ultrasonography shows intra-amni-
otic sludge as suspended hyperechogenic material near the uterine 
cervix in the amniotic fluid. It could indicate intrauterine microbial 
invasion. Intra-amniotic sludge also represents an independent risk 
factor both for histologic chorioamnionitis and microbial coloniza-
tion of the amniotic cavity; and for preterm premature membrane 
rupture and spontaneous preterm delivery. The combination of 
sludge and a CL <25 mm results in a higher risk for sPTB delivery 
at <28 and 32 weeks, than that of a short cervix alone. There is no 
sufficient evidence that intra-amniotic sludge alone can better the 
prediction accuracy already provided by CL [23].
The detachment of fetal membranes from the decidua, at the 
level of the internal os, ‘the moon sign’, is reported to be asso-
ciated with an increased risk of premature preterm rupture of 
membranes and sPTB [25,26].
Factors that affect the value of CL for the prediction of 
spontaneous sPTB: gestational age, patient obstetrical 
& medical history, symptoms & number of fetuses
Gestational age
CL before 14 weeks is usually normal, except in women with a 
previous large cone biopsy or recurrent second trimester miscar-
riages. It is usually therefore not very effective to use TVU CL to 
screen for sPTB before 14 weeks, because at this gestational age 
CL can be falsely reassuring due to the endocervical canal con-
tinuity with the lower uterine segment. Nonetheless, the earlier 
in gestational age the short TVU CL is detected, the higher the 
percentage risk of preterm birth.
The biological variation of CL, as measured by endovaginal 
ultrasound in the second trimester of pregnancy, is normally dis-
tributed and resembles a normal bell-shaped curve. Figure 3 is a 
graphic summary of the longitudinal course of CL during singleton 
pregnancies, between 12 and 32 weeks [27]. At 24 weeks gestation, 
the 50th percentile is approximately 35 mm and the tenth and 19th 
percentiles are 25 and 45 mm, respectively. The tenth percentile is 
25 mm  at 24 weeks for a low-risk population. Using 25 mm as a 
cut off for CL in a low-risk population with a singleton pregnancy, 
the sensitivity and the positive prediction values for sPTB before 
35 weeks gestation are 37 and 18%, respectively [7]. The relative 
risk of sPTB before 35 weeks is inversely related to TVU CL [7]. 
Figure 1. Black lines indicate the correct measurement of cervical length in the different shapes of cervical length: T, Y, V and U.
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Patients with a CL <15 mm have an approximate 50% likelihood 
of preterm delivery <32 weeks, regardless of risk factors [28–30]. It 
is also possible to calculate the individual risk for sPTB based on 
CL and other risk factors [30].
In an unselected European population of 24,640 pregnant 
women screened at 20–25 weeks gestation, only 413 women (1.7%) 
women showed CL ≤15 mm [31]. In an unselected North American 
population of 32,091 pregnant women screened at 19–23 weeks 
gestation, 733 (2.3%) showed CL between 10 and 20 mm [32].
Although the measurement of CL has become a fundamental 
part of clinical practice, several obscure points remain and most 
women with a short cervix (especially without a  history of sPTB) 
deliver at term without intervention. One explanation of the low 
sensitivities and positive predictive value of CL <25 mm is due to 
the fact that in a low-risk  population, the incidence of sPTB is low.
Patient obstetrical & medical history
Patients with a history of sPTB show an increased risk of sPTB 
in subsequent pregnancies [16,33]. In the Preterm Prediction 
Study, Iams et al. reported that in patients with a prior spon-
taneous preterm birth, the recurrence risk of preterm birth 
varies widely according to both fetal fibronectin and CL at 
22–24 weeks [34].
The best predictive value of CL is shown in a high-risk popu-
lation with previous sPTB. Most women who deliver preterm, 
especially if they have had a previous sPTB, show CL <25 mm 
between 16 and 24 weeks. Short CL in pregnancy has been related 
to repetitive preterm birth and women with a short cervix during 
pregnancy are more likely to have had a previous sPTB [33,34]. The 
association between CL and sPTB is strongest in women with a 
prior sPTB, and this association is particularly evident when the 
previous sPTB occurred before 32 weeks [34–36].
TVU CL <3 cm between 24 and 30 weeks in women with his-
tory of sPTB is predictive of sPTB in both the two  subtype groups 
of high-risk women: premature preterm rupture of membranes 
and intact membranes at the beginning of sPTB [37].
In a prospective, blinded observational study conducted in 
women with singleton pregnancies who had experienced at least 
one prior sPTB before 32 weeks, TVU CL less than 25 mm at 
16–18 weeks gestation was a significant predictor of sPTB before 
35 weeks. The sensitivity and the positive predictive value for 
sPTB before 35 weeks were 69 and 55%, respectively [38]. A his-
tory of more than one induced abortion is also a risk factor for 
short CL, with a relative risk for sPTB of 3.3 [39].
Besides previous sPTB, short CL during pregnancy can be 
the consequence of several factors: congenital malformations 
[40,41], previous surgery of the uterine cervix [42–44], subclinical 
intra-amniotic infection and/or inflammation [45–49] and cervical 
 insufficiency [50,51].
Among congenital malformation groups, women pregnant with 
a unicornuate uterus have been reported to show the highest inci-
dence of cervical shortening and sPTB [52]. The number of sPTB 
increases with the number of previous conizations [42].
In asymptomatic singleton pregnancies at 14–24 weeks with a 
short cervix of less than 25 mm, amniocentesis identifies microbial 
invasion in 9% of the women if Mycoplasma and Ureaplasma are 
also cultured for. Of those, 40% delivered before 32 weeks [53], 
 underlying the relationship between inflammation/infection and 
sPTB.
Patients with symptoms of labor
In pregnancies with symptoms of spontaneous preterm labor 
(PTL), the clinical dilemma revolves around the issue of 
whether the woman is in true PTL requiring hospitalization and 
administration of tocolytics in order to prolong pregnancy for 
induction of fetal lung maturity. Symptoms consist of  painful 
contractions and/or leaking fluid in the case of preterm prema-
ture rupturing of membranes, bleeding as an indicator of pla-
cental abruption, and fever as an indicator of chorioamnionitis. 
These women can be identified by TVU CL at presentation. 
The women with PTL at highest risk of PTB are those with a 
CL of <15 mm [54].
Ness proposes the use of a protocol in which the combination 
of TVU CL and fetal fibronectin is used for the management of 
women with threatened preterm labor at 24–34 weeks of gestation 
identifying women in whom treatment can provide benefit and 
optimizing use of resources (Figures 2 & 4) [55].
Amniocentesis and TVU CL were carried out in singleton preg-
nancies admitted in PTL, in order to examine the association 
between short CL and microbial invasion in the amniotic cavity. 
Microbial invasion, mainly Ureaplasma urealyticum, was found 
in 26% of the women with a CL of less than 15 mm, compared 
with 4% in those with a cervix of more than 15 mm, and 1.9% 
when the cervix length was more than 30 mm [56].
TVU appears to be safe in patients with preterm premature 
rupture of membranes and does not increase the risk of infection, 
although there are conflicting results about the predictive value of 
CL for latency [57,58]. A TVU CL <10 mm and cervical funneling 
>75% shows a predictive role for preterm premature rupture of 
membranes in high-risk patients [59]. There is a relation between 
TVU CL and vaginal bleeding during pregnancy.
Figure 2. Measurements of the cervix with funneling. 
(A) Funnel length, (B) functional length and (C) funnel width. 
Adapted with permission from [20].
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In women with threatened labor, the only independent predictors 
of delivery before 35 weeks are CL (OR: 0.84; 95% CI: 0.81–0.87) 
and vaginal bleeding (OR: 5.64; 95% CI: 2.20–14.42) [60].
Multiple gestation
Twin pregnancies represent a relevant but disproportionate part 
of all preterm births. For women carrying twins, a short cervix at 
24 weeks is one of the most important risk factors associated with 
sPTB. In a prospective prediction study on women with twins, CL 
≤25 mm measured at 24 weeks was significantly associated with 
sPTB at <32, <35 and <37 weeks. When performed at 28 weeks, 
however, a short cervix was significantly associated with sPTB 
only at <35 weeks [61].
A systematic review and meta-analysis estimates CL accu-
racy in the prediction of sPTB in women with twin pregnan-
cies, and supplies evidence that in twin pregnancies TVU CL at 
20–24 weeks gestation is the best predictor of sPTB in asymp-
tomatic women. Among asymptomatic women, a CL ≤20 mm 
at 20–24 weeks gestation predicts sPTB at <32 and <34 weeks 
gestation, whereas a CL ≤25 mm predicts preterm birth at 
<28 weeks gestation [62]. However, the negative predictive value 
is quite low, so a normal CL is less accurate 
in predicting the absence of sPTB. CL is 
less accurate at predicting sPTB <37 weeks 
of gestation. In addition, in this group of 
patients, TVU CL has limited accuracy in 
predicting sPTB women in which the test 
is performed >24 weeks of gestation.
Among twin gestation women threaten-
ing preterm labor, the measurement of CL 
has minimal predictive accuracy for pre-
term birth <34 and <37 weeks of  gestation 
[62]. There are limited data regarding the 
predictive accuracy of TVU CL performed 
<20 weeks of gestation [62].
Another systematic review and meta-anal-
ysis in asymptomatic women with multiple 
pregnancies confirms that second trimester 
CL is a predictor of preterm birth [63]. In 
advancing gestation, CL was reported to 
decrease more in triplet pregnancies than in 
twins [64]. Specifically, CL was predicted to 
decrease by 0.6 mm per week in singletons, 
0.9 mm in twins and 1.2 mm in triplets 
(Figure 5). In a study of 63 triplets, a CL cut-
off of 2 cm, prior to 28 weeks gestation, is 
significantly  associated with sPTB [65].
The value of CL in addressing 
therapeutic strategies to prevent 
sPTB
The therapeutic strategies used to reduce 
the rate of sPTB are the use of progestogens, 
which includes 17α-hydroxy-progesterone 
caproate given intramuscularly and natural 
progesterone given vaginally as a gel or as a suppository cervical 
cerclage and more recently, cervical pessary.
Progestogens
In the last decade, several randomized controlled trials assessing 
the effect of progestogens in reducing the rate of sPTB have been 
reported. In 2003, two studies demonstrated the role of progesto-
gens in reducing the rate of sPTB in asymptomatic women at risk 
due to previous sPTB [66,67].
The action of progesterone and how it prevents sPTB has been 
the focus of various investigations. The most recognized mecha-
nisms are generally the antinflammatory effect, which interacts 
with the inflammatory process that induces sPTB, and a local 
increase of progesterone that balances the functional decrease 
leading to sPTB [68–70].
Specifically, Meis et al. using 17α-hydroxyprogesterone 
caproate (250-mg intramuscular injections weekly) in women 
with documented history of a singleton sPTB starting between 
16 and 20 weeks gestation until 36 weeks or earlier delivery, 
demonstrated a reduction in the rate of recurrent spontaneous 
preterm delivery and in the likelihood of several complications 
Figure 3. Cervical length by gestational age. The lower and upper edges of each 
box plot denote the 25th and 75th percentiles, respectively, and the horizontal line inside 
the box denotes the median. The vertical lines extend out up to 1.5-times the 
interquartile range (the height of the box). The width of each box plot is proportional to 
the square root of the number of measurements (n = 2601).  
Reproduced with permission from [27].
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in their infants [66]. da Fonseca et al. used vaginal progester-
one (100 mg daily) and monitored uterine contractions with an 
external tocodynamometer once a week for 60 min, between 24 
and 34 weeks of gestation, on a population of high-risk women 
with a history of singleton sPTB. Here, prophylactic cervical 
cerclage and uterine malformation showed less frequent uterine 
contractions and preterm delivery [67]. In both of these studies, 
CL was not measured.
In 2007, O’Brien gave vaginal progesterone (90 mg daily) to 
women with a history of sPTB starting at 18 and 22 6/7 weeks 
gestation until 37 weeks or earlier delivery or premature rupture 
of membranes, and demonstrated that prophylactic treatment 
with vaginal progesterone did not reduce the frequency of 
recurrent preterm birth ≤32 weeks in women with a history 
of spontaneous preterm birth. At admittance, the mean TVU 
CL was 37 mm [71]. In the same year, Fonseca et al., for the 
first time showed that progesterone (micronized  progesterone 
gel, 200-mg vaginally daily) was useful in reducing the rate of 
sPTB also in women without previous sPTB but with a very 
short CL (≤15 mm) between 20 and 23 6/7 weeks gestation. 
This study for the first time proposed a strategy of routine 
screening of pregnant women by TVU measurement of CL 
at 20–25 weeks in order to select women with a CL ≤15 mm 
that should undergo prophylactic administration of vaginal 
Figure 4. Management protocol using cervical length and fetal fibronectin for symptomatic patients with threatened 
preterm labor. 
CL: Cervical length; FFN: Fetal fibronectin test; PTB: Preterm birth; PTL: Preterm labor; TVU: Transvaginal ultrasonography.  
Reproduced with permission from [55].
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micronized progesterone [31]. More recently, Hassan et al., using 
vaginal progesterone gel (90 mg daily) between 20 and 23 + 6 
gestation weeks until 36 + 6 weeks in singleton women with a 
short cervix (10–20 mm), showed a 45% reduction in the rate 
of preterm birth before 33 weeks gestation and with improved 
neonatal outcome [32].
The use of vaginal progesterone in asymptomatic women with 
a short cervix (≤25 mm) in the mid-trimester has been the subject 
of a recent meta-analysis that concluded that this strategy induces 
a 42% reduction in the rate of preterm birth before 33, 35, 34, 
30 and 28 weeks gestation, and also 43% of composite neonatal 
mortality and morbility [72]. The authors recommended TVU CL 
in all pregnant women between 19–24 weeks gestation (universal 
screening) and the use of vaginal progesterone for those with a 
short cervix (≤25 mm). There were no differences found regard-
ing the efficiency of doses of 90–100 or 200 mg/day of vaginal 
progesterone.
To date, four proposed interventions using progestogens in 
order to reduce the rate of sPTB have been compared: no screen-
ing or treatments; universal screening to detect women with CL 
≤15 mm who will receive 200 mg of vaginal progesterone from 
diagnosis until 33 weeks 6 days; high-risk screening using CL 
in woman at increased risk of sPTB to detect those with a short 
CL ≤15 mm who will be treated with vaginal progesterone gel 
and standardization of care using 19α-hydroxyprogesterone 
acetate (weekly injections) in women with previous sPTB. An 
estimate has been made based on these four proposed strategies 
to reduce the rate of sPTB in order to see which is the most cost 
effective, and concluded that universal transvaginal screening 
for short CL and treatment with vaginal progesterone may be 
the most cost effective in the reduction of the risk of PTB [73]. 
On the basis of all these observations, 
the American College of Obstetricians 
Gynecologists has cautiously opened 
toward equal universal cervical screen-
ing in singleton gestations without prior 
PTB, and practitioners who decide to 
implement universal screening are rec-
ommended to follow one of the proposed 
protocols [31,32,62,68,69]. Pregnant patients 
at risk for sPTB, because of previous 
PTB in their history, are strongly recom-
mended to take progesterone supplements 
starting at 16–24 weeks [74]. In woman 
with prior sPTB, if the TVU CL shortens 
to <25 mm at <24 weeks, cerclage may be 
offered. The Society for Maternal Fetal 
Medicine also proposed similar recom-
mendations, and states that in singleton 
gestations, without prior PTB and short 
CL ≤20 mm at 24 weeks, vaginal proges-
terone, either 90 mg gel or a 200 mg sup-
pository, is associated with a reduction in 
PTB and perinatal morbidity, and can be 
offered in these cases [75]. The algorithm 
proposed by the Society for Maternal-Fetal Medicine for the use 
of progestogens in reducing the rate of PTB is shown in Figure 6.
Cervical cerclage
Cervical surveillance with sonography can select appropriate 
candidates who could benefit from cerclage. Ultrasound indi-
cated cerclage has been reported to reduce the risk of recurrent 
PTB in singleton gestation with a short cervix. In contrast, 
with twins, cerclage is associated with a significantly higher 
incidence of sPTB and for this reason is contraindicated [76]. 
These data regarding ultrasound indicated cerclage has also 
been confirmed by a randomized clinical trial that demon-
strated cervical cerclage is a therapeutic strategy in singleton 
pregnant women with a prior PTB that occurred at less than 
34 weeks of gestation, when CL is less than 25 mm before 
24 weeks of gestation. In women with a prior sPTB less than 
34 weeks and CL less than 25 mm, cerclage reduced previable 
birth and perinatal mortality but did not prevent birth at less 
than 35 weeks, unless CL is less than 15 mm [77]. Meta-analysis 
of five randomized trials of cerclage versus no cerclage, which 
met strict inclusion criteria, that is, singleton pregnancy, short 
CL on TVU before 24 weeks gestation and previous sPTB 
before 35 weeks gestation, showed that in this select group, 
cerclage was associated with a significantly lower preterm birth 
(by 30%; relative risk [RR]: 0.70; 95% CI: 0.55–0.89) and 
perinatal morbidity and mortality (by 36%; RR: 0.64; 95% CI: 
0.45–0.91) [78]. Clinical guidelines recommend ultrasound cer-
vical cerclage in singleton gestation with prior sPTB if the TVU 
CL shortens to <25 mm before 24 weeks [74,75,79]. Figure 7 shows 
a care algorithm for asymptomatic women with multiple prior 
sPTB or spontaneous stillbirth [80].
Figure 5. Predicted cervical length change among singleton, twin and triplet 
pregnancies, across gestation. 
Reproduced with permission from [64].
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Cervical pessary
Cervical pessary is a silicone device that has 
been used over the past 50 years to reduce 
the rate of sPTB [81]. Before 2012, more than 
30 retrospective or case controlled studies 
showed that a cervical pessary can be used 
as a preventive strategy for patients at risk 
of sPTB [82,83]. In 2012, a randomized, con-
trolled trial that investigated whether the 
insertion of the Arabin cervical pessary in 
singleton pregnant women with a TVU CL 
less than 25 mm at 20–23 weeks of gestation 
reduced the rate of early preterm delivery, 
showed a statistically significant reduction 
in spontaneous delivery before 34 weeks 
of gestation in the pessary compared with 
the expectant management groups, and no 
serious adverse effects associated with the 
use of a cervical pessary were reported. 
The authors suggested that although the 
mechanism of action of cervical pessary 
remains to be clarified, the positive effect 
of the use of a pessary relies on its mechan-
ical ability to bend the cervix backwards, 
changing the uterocervical angle, which 
not only strengthens the cervical canal but 
also diminishes the contact of intact mem-
branes with the vagina, somehow preserving 
its integrity [84]. More recently, the effective-
ness of the use of Arabin cervical pessary in 
the reduction of the rate of sPTB has also 
been demonstrated in multiple pregnancy 
when the CL at 16–20 weeks is less than 
the 25th  percentile, which corresponded to 
38 mm [85].
Expert commentary
Recent research has clarified the best approach in measuring 
CL; the value of TVU CL in predicting PTBs when measured 
mid-trimester in asymptomatic patients, the use of TVU CL 
in screening patients with previous PTBs or second trimester 
losses in order to identify those that need therapeutic strategy 
and the usefulness of TVU CL in symptomatic singleton preg-
nancy to best select women for intervention such as tocolysis 
and induction of lung maturity.
CL is most accurately measured by TVU. In singleton preg-
nancy, the CL measured between 16 and 24 weeks of gestation is a 
good indicator of a pregnant woman’s risk of PTB. CL is normally 
distributed, and decreases slightly from 24 weeks onward. At 
24 weeks gestation, the average CL is 35 mm; the 25th percentile 
is 30 mm; the tenth percentile is 25 mm; the fifth percentile is 
22 mm and the first percentile is 13 mm. The shorter the CL the 
higher the risk of PTB [7].
In pregnant patients at risk for previous sPTB prophylac-
tic treatment with  progestogens, both intramuscularly and 
intravaginally has been shown to be  effective [66,67]. In sin-
gleton women with a history of less than three early sPTB 
and/or second trimester losses, both weekly treatment with 
17α-hydroxyprogesterone caproate and monitoring CL every 
2 weeks, starting at 16 weeks, is  recommended. In these women, 
monitoring CL until 23 weeks, can identify women with CL 
<25 mm, and these women would be recommended cervical 
cerclage [66].
In singleton patients at risk of sPTB, vaginal administration of 
progesterone reduces the incidence of preterm delivery in the pro-
gesterone group to 13.8 (ten out of 72) and 28.5% (20 out of 70) 
in the placebo group (p = 0.03). Mean contraction frequency for 
each gestational week studied was significantly greater for the 
placebo group than the progesterone group [67].
In singleton symptomatic patients with no history of PTBs 
and or STL, CL screening can identify those who do not need 
tocolysis and steroids, versus those who need intervention. In 
particular, CL >30 mm that remains stable does not need any 
intervention, while women with CL between 20 and 30 mm 
combined with a positive fetal fibronectin test or CL <20 mm 
Figure 6. Algorithm for use of progestogen in prevention of preterm birth in 
clinical care both in women with and without prior spontaneous preterm birth. 
†If TVU CL screening is performed.  
‡17P 250 mg intramuscularly every week from 16–20 weeks to 36 weeks.  
§e.g., daily 200-mg suppository or 90-mg gel from time of diagnosis of short CL to 
36 weeks.  
17P: 17α-hydroxyprogesterone caproate; CL: Cervical length; PTB: Preterm birth; 
TVU: Transvaginal ultrasound.  
Reproduced with permission from [75].
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Key issues
• Using cervical length (CL), the following three points ‘how’, ‘when’ and ‘what’ are defined as following: how: transvaginal 
ultrasonography (TVU) is the gold standard to investigate CL. When: between 16 and 24 weeks. What: CL less than 25 mm in singleton 
asymptomatic women with previous spontaneous preterm birth (sPTB). CL less than 20 mm in singleton asymptomatic women with no 
prior sPTB. CL less than 25 mm in twins asymptomatic women.
• The five important factors that affect the prevention of sPTB by using TVU CL are CL measurement, gestational age, number of fetuses, 
symptoms and other risk factors for sPTB such as patient obstetrical and medical history.
• The population categories in which TVU CL can be applied can be differentiated into asymptomatic and symptomatic pregnant women. 
In the group of asymptomatic patients, whether they are singleton with or without prior PTB, or multiples, the gestational age at which 
the test should be performed is 16–23 6/7 weeks.
• In symptomatic patients, whether they have cervical insufficiency or preterm labor or premature rupture of membranes or bleeding or 
more than one of these symptoms, the gestational age at which TVU CL is performed is usually between about 24 and 34 weeks.
• Pregnant patients at risk for sPTB, because of previous in their history, are strongly recommended to take a progestagen supplement 
starting at 16–24 weeks. In these women with prior sPTB, if the TVU CL shortens to <25 mm at <24 weeks, cerclage may be offered.
• In singleton gestations, without prior sPTB but with short CL ≤20 mm at 24 weeks, vaginal progesterone, either 90 mg gel or a 200 mg 
suppository, is associated with a reduction in PTB and perinatal morbidity, and can be offered in these cases.
• Clinical guidelines recommend ultrasound cervical cerclage in singleton gestation with prior sPTB if the TVU CL shortens to <25 mm 
before 24 weeks.
• The insertion of the Arabin cervical pessary in singleton pregnant women with a TVU CL less than 25 mm at 20–23 weeks of gestation 
reduced the rate of early sPTB before 34 weeks of gestation in a recent trial.
should probably receive admission steroids for fetal  maturation 
and tocolysis if contracting. Ultrasound indicated cervical 
 cerclage in singleton gestation with prior sPTB is  recommended 
if TVU CL shortens to less than 25 mm before  24 weeks [77].
Recently, promising data on the use of Arabin cervical pessary in 
reducing the rate of sPTB both in singleton and twin pregnancies 
have been reported, but more studies are 
necessary to confirm these results.
Five-year view
From the scientific point of view, in the 
future, randomized controlled studies using 
TVU CL as a screening test for patients at 
risk of sPTB will investigate the comparison 
of the efficacy of vaginal progesterone and 
cerclage and vaginal progesterone and pes-
sary in the prevention of sPTB. The possi-
bility of avoiding surgical procedures, such 
as a cerclage, is attractive and knowledge of 
the specific advantages of using a drug or 
mechanical device will help to identify the 
best customized treatment for each patient. 
Moreover, the possible cumulative effect of 
using combination approaches (e.g., pro-
gesterone and cerclage) should be explored. 
From the clinical point of view, TVU CL 
at 18–24 weeks will become an increasingly 
integral part of universal screening for sPTB 
offered to all of the pregnant population.
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Figure 7. Care algorithm for asymptomatic women with multiple prior 
spontaneous preterm birth or second-trimester losses.  
17P: 17α-hydroxyprogesterone caproate; IM: Intramuscular; PTB: Preterm birth;  
STL: Second trimester losses.
Asymptomatic women with multiple prior PTB or STL
17P prophylaxis (250 mg IM weekly from 16–36 week)  
≤3 early PTBs and/or ≤2 STL
Consider history indicated
(prophylactic cerclage) at 12–14 wks
Cervical length <25 mm  
Cerclage
≥3 early PTBs and/or ≥2 STL
Cervical ultrasound every 2 weeks
at 16–23 week  
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